Cargando…

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications

Despite distinct clinical entities, the myeloproliferative neoplasms (MPN) share morphological similarities, propensity to thrombotic events and leukemic evolution, and a complex molecular pathogenesis. Well-known driver mutations, JAK2, MPL and CALR, determining constitutive activation of JAK-STAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morsia, Erika, Torre, Elena, Poloni, Antonella, Olivieri, Attilio, Rupoli, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100530/ https://www.ncbi.nlm.nih.gov/pubmed/35562964 http://dx.doi.org/10.3390/ijms23094573

Ejemplares similares

PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.
por: Morsia, Erika, et al.
Publicado: (2023)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
por: Easwar, Arti, et al.
Publicado: (2021)

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
por: Morsia, E, et al.
Publicado: (2021)

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology
por: Chia, Yuh Cai, et al.
Publicado: (2023)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

A rare case of aCML associated with CNS involvement and with aggressive clinical course
por: Lame, Dorela, et al.
Publicado: (2023)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Genetic basis and molecular profiling in myeloproliferative neoplasms
por: Luque Paz, Damien, et al.
Publicado: (2023)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil
por: Torres, Dania G., et al.
Publicado: (2023)

Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms
por: MAKANI, Zahra, et al.
Publicado: (2017)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
por: Jang, Mi-Ae, et al.
Publicado: (2020)

Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics
por: Nann, Dominik, et al.
Publicado: (2021)

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients
por: Langabeer, Stephen
Publicado: (2022)

Cytokines frequently implicated in myeloproliferative neoplasms
por: Wang, Yingying, et al.
Publicado: (2019)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View
por: Petruk, Cheryl, et al.
Publicado: (2020)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

P1109: EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.
por: Morsia, Erika, et al.
Publicado: (2023)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms
por: Stivala, Simona, et al.
Publicado: (2021)

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology
por: Combaluzier, Sophie, et al.
Publicado: (2023)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

AKT is a therapeutic target in myeloproliferative neoplasms
por: Khan, Irum, et al.
Publicado: (2013)

Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
por: Brkic, Sime, et al.
Publicado: (2020)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms
por: Araki, Marito, et al.
Publicado: (2017)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)

Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic
por: Langabeer, Stephen E.
Publicado: (2020)

Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?
por: Langabeer, Stephen E.
Publicado: (2020)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
por: Abbou, Norman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ubbvlc034ksm3l9t0pdtm9iulo